A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Adverse Events

  Measured over: From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)

• Number of Participants Who Died

  Measured over: From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)

• Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities

  Measured over: From first dose (Day 1) and up to 6 weeks

• Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities

  Measured over: From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months)

• Part 2C: Objective Response Rate (ORR)

  Measured over: From first dose (Day 1) and up to 24 weeks

• Part 2C: Duration of Response (DOR)

  Measured over: From first dose (Day 1) and up to 24 weeks

• Part 2C: Progression Free Survival Rate at Week 24

  Measured over: Week 24

Changes Tremor has spotted